GovChime
Notice ID: b4349caa0f7448f1ac7962e8f7806008Award NoticeAwardedArchived

Award to SIRTEX MEDICAL, INC.

Awarded on June 25, 2026. Full description on SAM.gov.

Awarded tounder HT941026PE102 (source: SAM.gov award notice)• $21.2K

Overview

Posted
June 25, 2026
Notice type
Award Notice
Set-aside
No Set aside used
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
DEFENSE HEALTH AGENCY HCD WEST
Last updated
Oct 29, 2026
First published
Last updated on SAM.gov
Award date
Jun 25, 2026
Award amount (SAM.gov award notice)
$21.2K

Identifiers

Solicitation number
HT941026N0076
Notice ID
b4349caa0f7448f1ac7962e8f7806008
Award number (PIID)
HT941026PE102

Description

Notice of award of firm fixed price contract HT941026PE102, awarded sole source to SIRTEX MEDICAL, INC.

Full description on SAM.gov

Award Overview

Award Number

HT941026PE102

Award Amount (SAM.gov award notice)

$21.2K

Award Date

Jun 25, 2026

Awardee

Awardee UEI

CWH2GM13A2V6

Awardee CAGE Code

45EE6

Original Solicitation

Notice ID: b4349caa0f7448f1ac7962e8f7806008

Posted Date: Jun 25, 2026

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • W81K0025PA231
    SIRTEX MEDICAL INC
    Department of DefenseNAICS 325412
    $182.2KSigned Jul 24, 2026
  • W81K0025PA231
    SIRTEX MEDICAL INC
    Department of DefenseNAICS 325412
    $182.2KSigned Dec 15, 2025
  • W81K0025PA231
    SIRTEX MEDICAL INC
    Department of DefenseNAICS 325412
    $182.2KSigned Dec 15, 2025
  • W81K0025PA231
    SIRTEX MEDICAL INC
    Department of DefenseNAICS 325412
    $182.2KSigned Sep 30, 2025
  • W81K0225PA014
    SIRTEX MEDICAL INC
    Department of DefenseNAICS 325412
    $19.4KSigned Mar 14, 2025

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

Showing 1 of 1 items

Document
Source
Agency
Posted Date
File Size
Actions
Special NoticeDEFENSE HEALTH AGENCY (DHA)Jun 25, 2026102.04 KB

Lifecycle

  1. 3
    Version 3Award NoticeArchivedCurrent

    Award to SIRTEX MEDICAL, INC.

    Notice b4349caa0f7448f1ac7962e8f7806008 on SAM.gov

Other notices for this solicitation

  1. Special NoticeRelated noticeJun 23, 2026

    Notice of Intent to Sole Source SIRTEX MEDICAL, INC

    Notice b9380b4ff3f64507b6812b9585fd754f on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
National Contract SPE2D2-23-D-0006 - Famotidine Related Notice: SPE2D2-22-R-0119
-AwardedOpen
See attached Notice of Intent to Sole Source HT941027N0010
-Special Notice11/23/2026
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil
-Market Research11/15/2026
Please see attached for the sources sought notice/market research survey and MPID.
-Market Research11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation10/26/2026

Additional Details

Solicitation Number

HT941026N0076

Archive Date

Jul 10, 2026

Office Address

CAMP PENDLETON, CA, 92055